S U M M A R Y1. The distribution of vitamin D and its metabolites in human tissues has been studied by the combined use of radioactive cholecalciferol and biological assays of antiricketic activity in tissue extracts.2. Injected radioactive cholecalciferol was cleared rapidly from the blood; unchanged vitamin D and various metabolites were detected subsequently in all tissues examined. The highest concentration of biological activity and radioactivity was in fat; this and, to a lesser extent, other tissues were shown to retain activity over a prolonged period of time.3. Adipose tissue and voluntary muscle are the principal sites of storage of vitamin D in man. Pre-existing tissue pools of vitamin D can, in some circumstances, invalidate the use of radioactively labelled cholecalciferol to trace the pattern of body distribution.4. Metabolically produced 25-hydroxycholecalciferol is also taken up from the blood into many tissues, probably by protein-binding. 5. Vitamin D is excreted in bile principally as more polar metabolites. Smaller amounts of cholecalciferol and 25-hydroxycholecalciferol are also excreted, and antiricketic activity has been demonstrated in the bile of individuals treated with vitamin D.6. An excess of cholecalciferol (or of 25-hydroxycholecalciferol) in the blood appears to be eliminated by the physicochemical processes of partition into tissue lipid and binding to tissue proteins. It is inferred tentatively that an increased concentration of vitamin D or of 25-hydroxycholecalciferol in the liver also causes an increased biliary excretion of these substances, and an increased hepatic formation and elimination of more polar metabolites of the vitamin.

No abstract

1. The metabolism of an intravenous pulse dose of double-isotope-labelled cholecalciferol has been studied in control subjects with widely differing states of vitamin D nutrition and in patients with primary disorders of parathyroid function. 2. The formation of labelled 1,25-dihydroxy-cholecalciferol [1,25-(OH)2D3] and labelled 24,25-dihydroxycholecalciferol [24,25-(OH)2D3] has been related to the prevailing concentrations in serum of 25-hydroxycholecalciferol [25-(OH)D3], immunoreactive parathyroid hormonel, calcium and orthophosphate (Pi). 3. In control subjects with relative vitamin D deficiency [serum 25-(OH)2D3 was related inversely to the serum 25-(OH)D3 and serum calcium, and directly to serum immunoreactive parathyroid hormone. No formation of 1,25-(OH)2D3 was detectable to form labelled 24,25(OH)2D3 preferentially. 4. No control subject produced significant amounts of both labelled 1,25-(OH)2D3 and labelled 24,25-(OH)2D3 simultaneously. 5. All subjects with primary hyperparathyroidism produced significant amounts of labelled 1,25-(OH)2D3 and labelled 24,25-(OH)2D3 simultaneously; the renal turnover of 25-(OH)D3 was apparently greater than in nutritionally matched controls. Serum labelled 1,25-(OH)2D3 in this disease was not correlated with serum 25-(OH)D3, immunoreactive parathyroid hormone, calcium or Pi. Production of labelled 24,25-(OH)2D3 was inappropriately high for the prevailing nutritional state. 6. The indirectly estimated their concentration of 1,25-(OH)2D3 showed only a fourfold variation in control subjects (45-180 pmol/l), compatible with its having a regulated hormonal function. 7. The data suggest that the production of 1,25-(OH)2D3 from a pulse dose of cholecalciferol is normally regulated, directly or indirectly, by the parathyroid hormone.

No abstract

No abstract